Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | CETP | P11597 | 3/20 | 0.36 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6104358 | 0.90 | ESR1 (0.41) | ESR1ESR2TTRALOX15BALOX15 | |
| SCHEMBL5504106 | 0.88 | ESR1 (0.51) | ESR1ESR2 | |
| SCHEMBL5502034 | 0.79 | ESR1 (0.56) | ESR1ESR2 | |
| SCHEMBL6103061 | 0.75 | ESR1 (0.57) | ESR1ESR2 | |
| SCHEMBL5498088 | 0.73 | LTA4H (0.44) | ESR1ESR2 | |
| SCHEMBL3021743 | 0.63 | CHRNB2 (0.61) | — | |
| SCHEMBL10375139 | 0.63 | SCN9A (0.49) | SIRT1 | |
| SCHEMBL5505501 | 0.62 | SIRT3 (0.45) | ALOX15ALOX12 | |
| SCHEMBL16959700 | 0.61 | TSHR (0.50) | TTR | |
| SCHEMBL16148652 | 0.59 | ESR1 (0.64) | ESR1ESR2TTRALOX15BALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778656-A1 | BENZOXAZEPINE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006023242-A1 | BENZOXAZEPINE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-02 | — | — | WO | disclosed |
| US-20060040917-A1 | Benzoxazepine derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040917-A1 | Benzoxazepine derivatives as selective estrogen receptor modulators | GPER1, ESR2, ESR1 | ESR1 3/4885ESR2 2/4885TTR 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.